Who are Famtozinameran 12 Years of age and older's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Low Dose PF-07328948, Raxtozinameran 6 months to 4 years of age, BNT162b2, BNT162b2 BA.4/5 bivalent, Tozinameran 5 to 11 Years of age.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/famtozinameran-12-years-of-age-and-older.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Famtozinameran 12 Years of age and older — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Famtozinameran 12 Years of age and older (famtozinameran-12-years-of-age-and-older) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Infectious Disease.

marketed monoclonal antibody SARS-CoV-2 virus Infectious Disease Vaccine Live · refreshed every 30 min

Target snapshot

Famtozinameran 12 Years of age and older (famtozinameran-12-years-of-age-and-older) — Pfizer. Famtozinameran works by targeting the SARS-CoV-2 virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Famtozinameran 12 Years of age and older TARGET	famtozinameran-12-years-of-age-and-older	Pfizer	marketed	monoclonal antibody	SARS-CoV-2 virus
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Low Dose PF-07328948	low-dose-pf-07328948	Pfizer	marketed	small molecule	SARS-CoV-2 virus
Raxtozinameran 6 months to 4 years of age	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus
BNT162b2	bnt162b2	Pfizer	marketed	vaccine	SARS-CoV-2 virus
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
Tozinameran 5 to 11 Years of age	tozinameran-5-to-11-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Famtozinameran 12 Years of age and older — Competitive Intelligence Brief. https://druglandscape.com/ci/famtozinameran-12-years-of-age-and-older. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab